Physicians' Academy for Cardiovascular Education

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD - Munich, Germany

Video navigation menu

  • Clinical GLP-1RA trials with kidney outcomes or monitored kidney events 01:19
  • Which endpoint in the composite endpoint is driving outcomes? 05:19
  • Outcomes in subgroups of patients 07:23
  • Why may GLP-1RAs confer kidney benefit? 09:59
  • An ongoing kidney outcomes trial with GLP-1RA in CKD patients 12:00

Exploratory analyses suggest that treatment with ___ may result in ___ decline of eGFR in patients with eGFR <60 ml/min compared to all patients.

  • A. liraglutide, but not semaglutide; more
  • B. liraglutide, but not semaglutide; lesser
  • C. liraglutide and semaglutide; similar
  • D. liraglutide and semaglutide; lesser
Show the correct answer.

Educational information

This lecture by Johannes Mann was part of the EBAC-accredited symposium "Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA" held during ERA EDTA Virtual Congress 2020.


Johannes Mann, Department of Nephrology and Hypertension, Erlangen-Neurenberg, and KfH Kidney Center, Munich, Germany


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Click here for the slides of this presentation Click here for the meeting report

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: